Iovance Biotherapeutics, Inc.
IOVA
$2.21
$0.083.51%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 250.43M | 241.53M | 212.68M | 164.07M | 90.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 250.43M | 241.53M | 212.68M | 164.07M | 90.86M |
| Cost of Revenue | 190.43M | 183.47M | 158.17M | 115.69M | 74.51M |
| Gross Profit | 60.00M | 58.06M | 54.51M | 48.38M | 16.35M |
| SG&A Expenses | 158.68M | 163.46M | 165.33M | 152.80M | 140.20M |
| Depreciation & Amortization | 9.01M | 9.73M | 9.73M | 9.73M | 9.73M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 661.75M | 652.16M | 611.46M | 559.35M | 520.82M |
| Operating Income | -411.33M | -410.64M | -398.78M | -395.28M | -429.96M |
| Income Before Tax | -398.33M | -389.73M | -378.62M | -375.01M | -416.14M |
| Income Tax Expenses | -697.00K | 188.00K | -3.26M | -2.83M | -6.15M |
| Earnings from Continuing Operations | -397.63 | -389.92 | -375.36 | -372.18 | -410.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -397.63M | -389.92M | -375.36M | -372.18M | -410.00M |
| EBIT | -411.33M | -410.64M | -398.78M | -395.28M | -429.96M |
| EBITDA | -376.80M | -377.31M | -366.04M | -363.12M | -399.46M |
| EPS Basic | -1.20 | -1.23 | -1.23 | -1.30 | -1.50 |
| Normalized Basic EPS | -0.75 | -0.78 | -0.79 | -0.83 | -0.96 |
| EPS Diluted | -1.20 | -1.23 | -1.23 | -1.30 | -1.50 |
| Normalized Diluted EPS | -0.75 | -0.78 | -0.79 | -0.83 | -0.96 |
| Average Basic Shares Outstanding | 1.33B | 1.27B | 1.22B | 1.16B | 1.11B |
| Average Diluted Shares Outstanding | 1.33B | 1.27B | 1.22B | 1.16B | 1.11B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |